Desmopressin
As of the edition of 20 October 2026, Desmopressin is a protein: marketed, first approved in 1982 (US); acts on AVPR1A, AVPR1B and AVPR2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Protein
- Brand name
- Ddavp
- First approved
- 1 January 1982 (US)
- Approvals on record
- 35 in 6 regions
- Holder of the most recent approval
- Eton Pharmaceuticals; 6 holders in all
- Registered trials
- 77, 9 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Mental health; Blood and lymph; Nervous system; Heart and blood vessels
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 11 | 3 | 2 |
| Phase 1 | 5 | 4 | 0 | 0 |
| Phase 2 | 10 | 6 | 1 | 2 |
| Phase 3 | 23 | 16 | 4 | 2 |
| Phase 4 | 18 | 9 | 2 | 3 |
| All trials | 77 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Later holder and Earlier holder | 1995 to now |
| Ferring Pharmaceuticals | Acquired holder and Lead sponsor of trials | 2007 to now |
| Serenity Pharmaceuticals | Later holder and Lead sponsor of trials | 2009 to now |
| Acerus Pharmaceuticals | Acquired holder | 2023 to now |
| Eton Pharmaceuticals | Later holder | 2026 to now |
| J Molner | Acquired holder | 2026 to now |